Get the Stockscreener App
0.84
4.99%
0.0399
Xortx Therapeutics Inc stock is traded at $0.84, with a volume of 31,026.
It is up +4.99% in the last 24 hours and down -11.47% over the past month.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.
See More
Previous Close:
$0.8001
Open:
$0.845
24h Volume:
31,026
Relative Volume:
0.27
Market Cap:
$4.38M
Revenue:
-
Net Income/Loss:
$-736.70K
P/E Ratio:
-84.00
EPS:
-0.01
Net Cash Flow:
$-4.14M
1W Performance:
+2.19%
1M Performance:
-11.47%
6M Performance:
+2.44%
1Y Performance:
-30.58%
1-Day Range:
$0.8123
$0.85
1-Week Range:
$0.70
$0.8698
52-Week Range:
$0.6608
$2.9799
Xortx Therapeutics Inc Stock (XRTX) Company Profile
Compare XRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XRTX
Xortx Therapeutics Inc
|
0.84 | 4.17M | 0 | -736.70K | -4.14M | -0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xortx Therapeutics Inc Stock (XRTX) Latest News
Risk vs reward if holding onto XORTX Therapeutics Inc.Trade Entry Report & Free Daily Entry Point Trade Alerts - Newser
Regression analysis insights on XORTX Therapeutics Inc. performancePortfolio Value Summary & AI Optimized Trading Strategy Guides - Newser
How to monitor XORTX Therapeutics Inc. with trend dashboardsJuly 2025 Macro Moves & Free Technical Pattern Based Buy Signals - Newser
Is XORTX Therapeutics Inc. still worth holding after the dipJuly 2025 PreEarnings & Real-Time Volume Surge Alerts - Newser
Published on: 2025-08-19 23:37:07 - Newser
Real time scanner hits for XORTX Therapeutics Inc. explainedWeekly Risk Summary & Growth Focused Stock Reports - Newser
Published on: 2025-08-19 23:16:36 - Newser
Visual analytics tools that track XORTX Therapeutics Inc. performanceJuly 2025 Chart Watch & Momentum Based Trading Ideas - Newser
XORTX Therapeutics Inc. stock daily chart insightsJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - Newser
Sector ETF Data Correlates with Strength in XORTX Therapeutics Inc.July 2025 Setups & Growth Focused Stock Reports - beatles.ru
Sector ETF performance correlation with XORTX Therapeutics Inc.GDP Growth & Verified High Yield Trade Plans - Newser
Can technical indicators confirm XORTX Therapeutics Inc.’s reversal2025 Valuation Update & Stepwise Entry and Exit Trade Signals - Newser
Is XORTX Therapeutics Inc. in a bullish channelWeekly Loss Report & Real-Time Price Movement Reports - newsimpact.co.kr
Is XORTX Therapeutics Inc. stock poised for growthWeekly Investment Summary & Fast Exit and Entry Strategy Plans - Newser
Volume spikes in XORTX Therapeutics Inc. stock – what they meanMarket Movement Recap & Safe Entry Zone Identification - Newser
Chart overlay techniques for tracking XORTX Therapeutics Inc.Market Risk Report & Real-Time Market Trend Scan - Newser
Using fundamentals and technicals on XORTX Therapeutics Inc.2025 Market Overview & Long-Term Growth Stock Strategies - Newser
Short Covering May Lift XORTX Therapeutics Inc. in Near TermQuarterly Earnings Summary & Fast Gain Stock Tips - metal.it
Will XORTX Therapeutics Inc. continue its uptrendRate Cut & Long-Term Capital Growth Strategies - Newser
Combining price and volume data for XORTX Therapeutics Inc.Bond Market & Weekly High Potential Stock Alerts - Newser
Has XORTX Therapeutics Inc. found a price floorWeekly Market Outlook & Safe Entry Trade Signal Reports - Newser
Form 6-KReport of foreign issuer [Rules 13a-16 and 15d-16] - ADVFN Brasil
XORTX Therapeutics Reports Financial Results for Mid-2025 - MSN
XORTX Therapeutics Inc. stock chart pattern explainedPortfolio Risk Report & Weekly Watchlist of Top Performers - Newser
Published on: 2025-08-16 03:34:09 - Newser
Published on: 2025-08-16 09:30:41 - metal.it
Is XORTX Therapeutics Inc. stock a growth or value playWeekly Stock Recap & Low Risk High Reward Ideas - beatles.ru
Leading vs lagging indicators on XORTX Therapeutics Inc. performanceM&A Rumor & Fast Entry High Yield Stock Tips - Newser
Smart tools for monitoring XORTX Therapeutics Inc.’s price actionMarket Risk Report & Short-Term High Return Ideas - Newser
Can XORTX Therapeutics Inc. scale operations efficiently2025 Buyback Activity & Trade Opportunity Analysis Reports - 선데이타임즈
What Fibonacci levels say about XORTX Therapeutics Inc. reboundIndex Update & AI Enhanced Trading Alerts - Newser
Is this a good reentry point in XORTX Therapeutics Inc.July 2025 Review & Capital Protection Trading Alerts - Newser
Is XORTX Therapeutics Inc. stock overhyped or has real potential2025 Price Momentum & Risk Controlled Stock Alerts - Newser
Should you hold or exit XORTX Therapeutics Inc. nowJuly 2025 Trade Ideas & Verified Short-Term Trading Plans - Newser
XORTX Therapeutics Completes $114,500 Private Placement to Fund Gout Programs - MSN
Can XORTX Therapeutics Inc. expand into new marketsMarket Risk Summary & Technical Pattern Based Buy Signals - thegnnews.com
Using R and stats models for XORTX Therapeutics Inc. forecastingTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Xortx Therapeutics Inc Stock (XRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):